Loading clinical trials...

Stereotactic Aspiration and Thrombolysis of Intracerebral Hemorrhage: a Prospective Controlled Study | Clinical Trials | Clareo Health

UNKNOWNNA

Stereotactic Aspiration and Thrombolysis of Intracerebral Hemorrhage: a Prospective Controlled Study

Stereotactic Aspiration and Thrombolysis of Intracerebral Hemorrhage: a Prospective Controlled Study（SATIH）

NCT00752024•Huazhong University of Science and Technology

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the superiority of effect of the modified micro-invasive aspiration and drainage and conservative medical therapy in the treatment of ICH spontaneously hypertensive scientifically.

Detailed Description

The stereotactic computed tomographic-guided aspiration and drainage is one of the best choices in the treatment of a large-scale deep supratentorial intracerebral hematoma. It uses hardware access technology, in a relatively short time to enter the hematoma center, with suction liquefaction technology. It has the advantage of a higher clearance rate of the hematoma, simple convenience, small trauma and low-cost. We carry on the suitable improvement in this technology's foundation in view of its deficiency, the introduction of the concept of the individual, will further reduce the rate of bleeding and mortality, improve survival, such as long-term quality of life. We will adopt scales such as the rate of rebleeding, mortality, complication,NIHSS, MRS, BI, GOS scale to analysis and evaluating efficacy and safety of this technology and conservative treatment in the treatment of HICH.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•CT diagnosis of spontaneous supratentorial intracerebral hemorrhage, the amount of bleeding more than 50 ml, and had neurological signs
•All income groups the incidence of medical records to be random, the time should be \< 69 hours to ensure that within 72 hours of the onset of the operation
•To be random, former GCS score \> = 5 points
•Systolic blood pressure \<= 200 mmHg, mean arterial pressure \<= 150 mmHg (if higher than this value, but as corresponding to this standard can be dealt with the group, and only reached the standard before they can ask for random)
•Fasting plasma glucose \<= 11.1 mmol / L (if higher than this value, but as corresponding to this standard can be dealt with the group, and only reached the standard before they can ask for random)
•Patients aged 18 to 80-year-old.
•Based on China's relevant laws, the patient himself or family members (only in patients with the loss of his ability to judge the acts of circumstances) agreed to participate in this study, a good compliance, to fully comply with random, in accordance with the decision by the treatment, patients himself Or family members must sign informed consent moreover.
•Patients themselves or their families (only in patients with the loss of his ability to judge the acts of circumstances) have willingness and ability to follow the research program, data collection and preservation of history and follow-up process of informed consent.

Exclusion Criteria

•Patients clotting mechanisms are obstacles or having the experience of the use of anticoagulant drug (PT\> 15s, APTT\> 40s, INR\> 1.4, platelet count \<100 × 10 9 / L).
•Cerebral hernia formed more than two hours
•The merger of other serious system failure (heart, liver and kidney, etc.) or a variety of end-stage disease with cerebral hematoma (such as renal failure late cerebral hemorrhage, blood disease with cerebral hemorrhage)
•Prior to the onset of a variety of reasons for the defect or neurological movement disorder
•A clear cause of cerebral hemorrhage such as intracranial aneurysm, or dynamic
•such as a venous malformation
•Intracranial or serious systemic infection
•Marked cognitive impairment or mental abnormality
•Other such as pregnancy, cancer

Locations (1)

Department of Neurology of Tongji Hospital, Huazhong University of Science and Technology

Wuhan, Hubei, China

Key Dates

Start Date

September 1, 2008

Primary Completion Date

September 1, 2010

Completion Date

December 1, 2010

Last Updated

September 15, 2008

Enrollment

ESTIMATED participants

Conditions

Hypertensive Intracerebral Hemorrhage

Interventions

YL-1 type of intracranial hematoma puncture needle

DEVICE

dehydrating agent, haemostatic

DRUG

Contacts

wei wang, doctor

CONTACT

86-027-8366-3648 daodetongji@163.com

zhouping tang, doctor

CONTACT

86--013971616328 ddjtzp@163.com

Efficacy and Safety Study of Urapidil Alone or With Esmolol in Treating Acute Hypertensive Intracerebral Hemorrhage

NCT06635707

Hypertensive Intracerebral Hemorrhage

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 15, 2008Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions